HK Stock Market Move | INNOVENT BIO (01801) up more than 6%, Masvidal peptide has excellent effects on weight reduction and lowering liver fat.

INNOVENT BIO (01801) rose more than 6%, rising 6.08% to HK$39.25 by the time of publication, with a turnover of HK$1.11 billion. On the news front, INNOVENT BIO recently reported multiple clinical trial data of Marsdupelide at the 2024 American Diabetes Association (ADA) Scientific Sessions. Patients who used a dose of 6 mg of Marsdupelide continuously for 32 and 48 weeks saw weight reductions of 13.38% and 14.84% respectively from baseline. In addition, Marsdupelide significantly improved liver metabolic function, with a 80.2% reduction in liver fat content after 48 weeks of using the 6 mg dose. China Tai International pointed out that this data is not inferior to the best-selling GLP-1 drugs in the world, semaglutide and tirzepatide. Applications for the indication of weight reduction for 6 mg and 4 mg doses of Marsdupelide were submitted in February 2024, and the company expects approval in the first half of 2025, slightly ahead of the original expectations of the bank.